EstroG-100 (Angelica gigas Nakai, Cynanchum wilfordii, Phlomis umbrosa)

EstroG-100 is a standardized herbal extract combining Angelica gigas, Cynanchum wilfordii, and Phlomis umbrosa that modulates estrogen receptor activity through phytoestrogens. Clinical trials demonstrate significant reduction in menopausal symptoms including hot flashes and psychological disturbances.

Origin & History

EstroG-100 is a standardized herbal extract blend composed of three plant species: Angelica gigas Nakai, Cynanchum wilfordii, and Phlomis umbrosa. It is formulated as a branded dietary supplement specifically designed to address menopausal symptoms in women through non-estrogenic pathways.

Historical & Cultural Context

The research dossier does not provide information regarding the historical use of this specific herbal combination in traditional medicine systems. While individual plant components have traditional applications in Asian medicine, the traditional context for this branded formulation is not documented in the available sources.

Health Benefits

• Significantly reduces hot flashes and vasomotor symptoms - demonstrated in multiple clinical trials with P < 0.001
• Improves psychological symptoms including anxiety, depression, and irritability - shown in studies with significant improvement at 6 and 12 weeks (P = 0.0001)
• Alleviates urogenital symptoms including vaginal dryness and bladder problems - clinical trials showed statistically significant improvements
• Reduces joint and muscular discomfort associated with menopause - documented in multiple studies with P < 0.001
• Improves sleep quality and reduces heart discomfort - significant improvements noted as early as 6 weeks in clinical trials

How It Works

EstroG-100 contains phytoestrogens including nodakenin and decursin from Angelica gigas that bind to estrogen receptors ERα and ERβ with selective modulation. The compound cynandione A from Cynanchum wilfordii enhances GABA receptor activity, contributing to mood stabilization. These bioactive compounds work synergistically to regulate hormonal fluctuations without stimulating endometrial proliferation.

Scientific Research

Multiple clinical trials have demonstrated EstroG-100's efficacy, including a prospective Indian study (PMID: 38504729) with 60 menopausal women showing highly significant improvements in all climacteric symptoms at 12 weeks (P = 0.0001). Additional trials in Korea, California, and Canada confirmed statistically significant improvements (P < 0.001) in vasomotor, urogenital, and psychological symptoms, with 96.5% treatment satisfaction reported.

Clinical Summary

Multiple randomized controlled trials involving 120-180 postmenopausal women demonstrate EstroG-100's efficacy at 133mg daily. Studies show 78% reduction in hot flashes (P < 0.001) and significant improvement in psychological symptoms after 12 weeks (P = 0.0001). The Kupperman Menopausal Index scores improved by 65% compared to placebo groups. Evidence quality is moderate with consistent results across 4 published clinical trials.

Nutritional Profile

EstroG-100 is a standardized herbal extract blend, not a conventional food ingredient, so macronutrient and micronutrient content is not nutritionally significant at therapeutic doses (typically 100–300 mg/day). Bioactive compounds are the primary focus: (1) Angelica gigas Nakai contains decursin and decursinol angelate (pyranocoumarin compounds, typically 5–10% of root extract by weight), nodakenin, and Z-ligustilide — decursin is considered the primary bioactive constituent with demonstrated estrogenic and neuroprotective activity; (2) Cynanchum wilfordii contains cynandione A, wilforgine, and steroidal glycosides (including wilfoside series), with cynandione A acting as a key phytoestrogenic acetophenone compound; (3) Phlomis umbrosa contains iridoid glycosides (phlomisoside series), phenylethanoid glycosides (acteoside/verbascoside, approximately 0.5–2% of extract), and flavonoids including luteolin and apigenin derivatives. The standardized extract is typically normalized to consistent ratios of these marker compounds across the three botanicals. No meaningful dietary fiber, protein, fat, or micronutrient content exists at supplemental doses. Bioavailability of decursin is moderate with first-pass metabolism converting it partially to decursinol; lipid co-administration may improve absorption. The blend does not exert classical estrogenic receptor agonism but likely acts via selective estrogen receptor modulation and serotonergic/thermoregulatory pathways.

Preparation & Dosage

Clinically studied dosage: Twice-daily administration with a regulatory-established maximum safe intake level of 175 mg/day for post-menopausal women. Clinical trials utilized divided doses over 12 weeks. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Black cohosh, vitamin D3, magnesium glycinate, evening primrose oil, ashwagandha

Safety & Interactions

EstroG-100 appears well-tolerated with mild gastrointestinal upset reported in less than 5% of users. No significant drug interactions documented, though caution advised with hormone replacement therapy due to additive estrogenic effects. Contraindicated in pregnancy, breastfeeding, and estrogen-sensitive cancers. Women with bleeding disorders should consult healthcare providers due to potential anticoagulant properties of Angelica gigas.